{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:19:15Z","timestamp":1775845155879,"version":"3.50.1"},"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Joint Key Program of the National Natural Science Foundation of China","award":["U22A20340"],"award-info":[{"award-number":["U22A20340"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060588"],"award-info":[{"award-number":["82060588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Key R&D Program of Autonomous Region Science and Technology Plan","award":["XZ202301ZY0011G"],"award-info":[{"award-number":["XZ202301ZY0011G"]}]},{"name":"the Young Doctor Academic Development Support Program of Tibet University","award":["ZDBS202216"],"award-info":[{"award-number":["ZDBS202216"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute Mountain Sickness (AMS) is a high-altitude-specific condition with variable prevalence and poorly defined risk factors. Despite growing global exposure to high-altitude environments, no systematic review has comprehensively synthesized AMS epidemiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the prevalence of AMS and critically evaluate evidence on risk factors associated with increased susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, Cochrane Library, Web of Science, CINAHL Plus, China Knowledge Resource Integrated Database (CNKI), Wanfang Database, Chinese Biomedical Database (CBM), and Weipu Database (VIP) were comprehensively searched for observational studies investigating the prevalence and risk factors of AMS from January 1, 2004 to December 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Review methods<\/jats:title>\n                    <jats:p>Original journal articles were included which met the inclusion criteria. The quality of the included studies was evaluated independently by two investigators. Meta-analysis was conducted using R software (v4.2.2), with estimates of AMS from pooled using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec006\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-eight studies (n\u2009=\u20092,705) were included. The pooled AMS prevalence was 48.25% (95% CI: 42.58\u201353.96%), with substantial heterogeneity (I\u00b2\u2009=\u200982.3%). Significant risk factors included extreme altitude (&gt;5500 m; RR\u2009=\u20091.89), rapid ascent (&lt;6 h; RR\u2009=\u20091.60), marked heart rate increase (&gt;20 bpm; RR\u2009=\u20092.35), and oxygen saturation decline (&gt;10%; RR\u2009=\u20092.02). Prior AMS history (RR\u2009=\u20091.36) and male sex (RR\u2009=\u20091.15) were also associated with higher risk, while older age (&gt;50 years) was protective (RR\u2009=\u20090.78).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec007\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AMS affects nearly half of high-altitude visitors. Altitude, ascent rate, cardiopulmonary response, and prior AMS history are key risk determinants. These findings support pre-exposure risk stratification, staged ascent protocols, and real-time physiological monitoring. PROSPERO CRD42024595365.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345796","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:27:57Z","timestamp":1775842077000},"page":"e0345796","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and risk factors for AMS: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"21","author":[{"given":"Xinzhu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyezi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangyi","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang","family":"Ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4999-8185","authenticated-orcid":true,"given":"Lanzi","family":"Gongga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"737","key":"pone.0345796.ref001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/pgmj.63.737.163","article-title":"Acute mountain sickness","volume":"63","author":"AD Wright","year":"1987","journal-title":"Postgrad Med J"},{"issue":"4","key":"pone.0345796.ref002","first-page":"337","article-title":"Current prevention and management of acute mountain sickness","volume":"65","author":"FJ Bia","year":"1992","journal-title":"Yale J Biol Med"},{"issue":"3","key":"pone.0345796.ref003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/152702902320604304","article-title":"Daniel vergara lope and carlos monge medrano: Two pioneers of high altitude medicine","volume":"3","author":"AC Rodr\u00edguez de Romo","year":"2002","journal-title":"High Alt Med Biol"},{"issue":"2","key":"pone.0345796.ref004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1580\/1080-6032-17.2.87","article-title":"Prevention of acute mountain sickness by acetazolamide in Nepali porters: A double-blind controlled trial","volume":"17","author":"P Hillenbrand","year":"2006","journal-title":"Wilderness Environ Med"},{"issue":"4","key":"pone.0345796.ref005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/ham.2018.0048","article-title":"Acute mountain sickness is reduced following 2 days of staging during subsequent ascent to 4300\u2009m","volume":"19","author":"BA Beidleman","year":"2018","journal-title":"High Alt Med Biol"},{"key":"pone.0345796.ref006","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.2017.16077","article-title":"Acute mountain sickness","volume":"318","author":"J Jin","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"pone.0345796.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291060","article-title":"Prevalence and knowledge about acute mountain sickness in the Western Alps","volume":"18","author":"MM Berger","year":"2023","journal-title":"PLoS One"},{"issue":"143","key":"pone.0345796.ref008","doi-asserted-by":"crossref","first-page":"160096","DOI":"10.1183\/16000617.0096-2016","article-title":"Acute high-altitude sickness","volume":"26","author":"AM Luks","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"4","key":"pone.0345796.ref009","first-page":"170","article-title":"Critical appraisal of the health research literature: prevalence or incidence of a health problem","volume":"19","author":"PL Loney","year":"1998","journal-title":"Chronic Dis Can"},{"issue":"2","key":"pone.0345796.ref010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/ham.2020.0150","article-title":"Predictive capacity of pulmonary function tests for acute mountain sickness","volume":"22","author":"E Small","year":"2021","journal-title":"High Alt Med Biol"},{"issue":"1","key":"pone.0345796.ref011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-023-03209-7","article-title":"Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: A randomized clinical trial","volume":"22","author":"M Liu","year":"2024","journal-title":"BMC Med"},{"issue":"2","key":"pone.0345796.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.05.034","article-title":"Budesonide versus acetazolamide for prevention of acute mountain sickness","volume":"131","author":"GS Lipman","year":"2018","journal-title":"Am J Med"},{"issue":"2","key":"pone.0345796.ref013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jemermed.2014.07.047","article-title":"Inhaled budesonide prevents acute mountain sickness in young Chinese men","volume":"48","author":"G-Z Chen","year":"2015","journal-title":"J Emerg Med"},{"issue":"10","key":"pone.0345796.ref014","article-title":"Inhaled budesonide and oral dexamethasone prevent acute mountain sickness","volume":"127","author":"C-R Zheng","year":"2014","journal-title":"Am J Med"},{"key":"pone.0345796.ref015","doi-asserted-by":"crossref","first-page":"109003","DOI":"10.1016\/j.biopha.2019.109003","article-title":"Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: A randomized double-blinded placebo-controlled clinical trial","volume":"116","author":"J Yang","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"pone.0345796.ref016","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-3756","article-title":"Reproducibility of acute mountain sickness in children and adults: A prospective study","volume":"127","author":"E Rexhaj","year":"2011","journal-title":"Pediatrics"},{"key":"pone.0345796.ref017","doi-asserted-by":"crossref","first-page":"102576","DOI":"10.1016\/j.tmaid.2023.102576","article-title":"Remote ischemic preconditioning improves spatial memory and sleep of young males during acute high-altitude exposure","volume":"53","author":"Y Wu","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"pone.0345796.ref018","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1249\/MSS.0000000000002232","article-title":"Endurance athletes are at increased risk for early acute mountain sickness at 3450 m","volume":"52","author":"M Sareban","year":"2020","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"pone.0345796.ref019","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100006","article-title":"Acetazolamide to prevent adverse altitude effects in COPD and healthy adults","volume":"1","author":"M Furian","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"pone.0345796.ref020","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14662","article-title":"Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: A randomized clinical trial","volume":"30","author":"Y Wang","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"pone.0345796.ref021","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/17461391.2021.1927197","article-title":"Repeated remote ischaemic preconditioning can prevent acute mountain sickness after rapid ascent to a high altitude","volume":"22","author":"Z Wang","year":"2022","journal-title":"Eur J Sport Sci"},{"issue":"8","key":"pone.0345796.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073185","article-title":"Association between body water status and acute mountain sickness","volume":"8","author":"H Gatterer","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"pone.0345796.ref023","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0333102415610876","article-title":"Hypoxia triggers high-altitude headache with migraine features: A prospective trial","volume":"36","author":"G Broessner","year":"2016","journal-title":"Cephalalgia"},{"issue":"4","key":"pone.0345796.ref024","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.wem.2023.09.002","article-title":"A Randomized Phase 2 Study to Evaluate Efficacy and Safety of AR36 for Prevention of Acute Mountain Sickness","volume":"34","author":"University of California San Francisco AR36 working group","year":"2023","journal-title":"Wilderness Environ Med"},{"issue":"2","key":"pone.0345796.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148206","article-title":"Acute mountain sickness symptom severity at the south pole: The influence of self-selected prophylaxis with acetazolamide","volume":"11","author":"MF Harrison","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"pone.0345796.ref026","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1152\/japplphysiol.00505.2017","article-title":"Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3,450 m","volume":"123","author":"MM Berger","year":"2017","journal-title":"J Appl Physiol (1985)"},{"issue":"32","key":"pone.0345796.ref027","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011788","article-title":"The effects of respiratory inhaled drugs on the prevention of acute mountain sickness","volume":"97","author":"X Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0345796.ref028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1580\/08-WEME-BR-247.1","article-title":"Ginkgo biloba does--and does not--prevent acute mountain sickness","volume":"20","author":"G Leadbetter","year":"2009","journal-title":"Wilderness Environ Med"},{"issue":"5","key":"pone.0345796.ref029","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0838.2012.01499.x","article-title":"Short-term intermittent hypoxia reduces the severity of acute mountain sickness","volume":"22","author":"M Wille","year":"2012","journal-title":"Scand J Med Sci Sports"},{"key":"pone.0345796.ref030","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1249\/MSS.0000000000001036","article-title":"Seven Passive 1-h Hypoxia Exposures Do Not Prevent AMS in Susceptible Individuals","volume":"48","author":"M Faulhaber","year":"2016","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"pone.0345796.ref031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/ham.2011.1005","article-title":"Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebo-controlled trial","volume":"12","author":"NP Talbot","year":"2011","journal-title":"High Alt Med Biol"},{"issue":"3","key":"pone.0345796.ref032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ana.21162","article-title":"Sumatriptan for prevention of acute mountain sickness: Randomized clinical trial","volume":"62","author":"S Jafarian","year":"2007","journal-title":"Ann Neurol"},{"issue":"8","key":"pone.0345796.ref033","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1055\/s-0032-1327577","article-title":"Effects of exercise and hypoxia on heart rate variability and acute mountain sickness","volume":"34","author":"K Mairer","year":"2013","journal-title":"Int J Sports Med"},{"issue":"6","key":"pone.0345796.ref034","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/echo.13189","article-title":"Altitude-induced pulmonary hypertension on one-day rapid ascent of mount fuji: Incidence and therapeutic effects of sildenafil","volume":"33","author":"M Iwase","year":"2016","journal-title":"Echocardiography"},{"issue":"2","key":"pone.0345796.ref035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/ham.2019.0087","article-title":"The effects of apnea training, using voluntary breath holds, on high altitude acclimation: Breathe-high altitude study","volume":"21","author":"N Shah","year":"2020","journal-title":"High Alt Med Biol"},{"issue":"3","key":"pone.0345796.ref036","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/CS20030187","article-title":"Magnesium for the prevention and treatment of acute mountain sickness","volume":"106","author":"L Dumont","year":"2004","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"pone.0345796.ref037","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archinte.165.3.296","article-title":"Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: A randomized, placebo-controlled trial","volume":"165","author":"T Chow","year":"2005","journal-title":"Arch Intern Med"},{"issue":"7","key":"pone.0345796.ref038","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1152\/japplphysiol.00329.2012","article-title":"Exercise intensity typical of mountain climbing does not exacerbate acute mountain sickness in normobaric hypoxia","volume":"113","author":"K Schommer","year":"2012","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0345796.ref039","doi-asserted-by":"crossref","first-page":"593938","DOI":"10.1155\/2015\/593938","article-title":"Influence of acute normobaric hypoxia on hemostasis in volunteers with and without acute mountain sickness","volume":"2015","author":"M Schaber","year":"2015","journal-title":"Biomed Res Int"},{"issue":"9","key":"pone.0345796.ref040","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.7863\/ultra.15.14.10060","article-title":"Optic nerve sheath diameter increase on ascent to high altitude: Correlation with acute mountain sickness","volume":"34","author":"NC Kanaan","year":"2015","journal-title":"J Ultrasound Med"},{"key":"pone.0345796.ref041","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1472-6882-13-298","article-title":"Rhodiola crenulata extract for prevention of acute mountain sickness: A randomized, double-blind, placebo-controlled, crossover trial","volume":"13","author":"T-F Chiu","year":"2013","journal-title":"BMC Complement Altern Med"},{"issue":"3","key":"pone.0345796.ref042","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3346\/jkms.2014.29.3.416","article-title":"Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: An open-label randomized controlled trial","volume":"29","author":"K Heo","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"4","key":"pone.0345796.ref043","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.wem.2012.08.001","article-title":"Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): Randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness","volume":"23","author":"JH Gertsch","year":"2012","journal-title":"Wilderness Environ Med"},{"issue":"4","key":"pone.0345796.ref044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/ham.2008.1029","article-title":"Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness","volume":"9","author":"MCT van Patot","year":"2008","journal-title":"High Alt Med Biol"},{"issue":"3","key":"pone.0345796.ref045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/ham.2011.0007","article-title":"Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial","volume":"12","author":"MGD Bates","year":"2011","journal-title":"High Alt Med Biol"},{"issue":"1","key":"pone.0345796.ref046","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/ham.2007.1037","article-title":"Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness","volume":"9","author":"B Kayser","year":"2008","journal-title":"High Alt Med Biol"},{"issue":"5","key":"pone.0345796.ref047","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/qjmed\/hcp026","article-title":"Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial","volume":"102","author":"JK Baillie","year":"2009","journal-title":"QJM"},{"issue":"9","key":"pone.0345796.ref048","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00421-011-1864-9","article-title":"Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole station","volume":"111","author":"S Lalande","year":"2011","journal-title":"Eur J Appl Physiol"},{"key":"pone.0345796.ref049","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/ham.2019.0034","article-title":"Are pre-ascent low-altitude saliva cortisol levels related to the subsequent acute mountain sickness score? Observations from a field study","volume":"20","author":"H Gatterer","year":"2019","journal-title":"High Alt Med Biol"},{"issue":"3","key":"pone.0345796.ref050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/ham.2007.1073","article-title":"Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans","volume":"9","author":"B Basnyat","year":"2008","journal-title":"High Alt Med Biol"},{"key":"pone.0345796.ref051","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.niox.2016.08.007","article-title":"Effects of dietary nitrate supplementation on symptoms of acute mountain sickness and basic physiological responses in a group of male adolescents during ascent to Mount Everest Base Camp","volume":"60","author":"PJ Hennis","year":"2016","journal-title":"Nitric Oxide"},{"issue":"1","key":"pone.0345796.ref052","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/ham.2009.1019","article-title":"Training in normobaric hypoxia and its effects on acute mountain sickness after rapid ascent to 4559 m","volume":"11","author":"K Schommer","year":"2010","journal-title":"High Alt Med Biol"},{"key":"pone.0345796.ref053","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ntt.2012.12.003","article-title":"Effects of acetazolamide on cognitive performance during high-altitude exposure","volume":"35","author":"J Wang","year":"2013","journal-title":"Neurotoxicol Teratol"},{"issue":"4","key":"pone.0345796.ref054","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1580\/06-WEME-OR-062R2.1","article-title":"Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollag\u00fce (3696 m) in northern Chile","volume":"18","author":"FA Moraga","year":"2007","journal-title":"Wilderness Environ Med"},{"issue":"3","key":"pone.0345796.ref055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.wem.2014.04.004","article-title":"Sleeping in moderate hypoxia at home for prevention of acute mountain sickness (AMS): a placebo-controlled, randomized double-blind study","volume":"25","author":"C Dehnert","year":"2014","journal-title":"Wilderness Environ Med"},{"issue":"1","key":"pone.0345796.ref056","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.wem.2010.10.009","article-title":"Spironolactone does not prevent acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group)","volume":"22","author":"B Basnyat","year":"2011","journal-title":"Wilderness Environ Med"},{"issue":"5","key":"pone.0345796.ref057","first-page":"413","article-title":"Cysteinyl leukotriene blockade does not prevent acute mountain sickness","volume":"75","author":"SR Muza","year":"2004","journal-title":"Aviat Space Environ Med"},{"issue":"3","key":"pone.0345796.ref058","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/ham.2009.1004","article-title":"Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters","volume":"10","author":"BA Beidleman","year":"2009","journal-title":"High Alt Med Biol"},{"issue":"6","key":"pone.0345796.ref059","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.annemergmed.2012.01.019","article-title":"Ibuprofen prevents altitude illness: A randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories","volume":"59","author":"PAINS Group","year":"2012","journal-title":"Ann Emerg Med"},{"issue":"3","key":"pone.0345796.ref060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.wem.2010.06.009","article-title":"Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: The Headache Evaluation at Altitude Trial (HEAT)","volume":"21","author":"JH Gertsch","year":"2010","journal-title":"Wilderness Environ Med"},{"issue":"2","key":"pone.0345796.ref061","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/ham.2014.1110","article-title":"Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)","volume":"16","author":"GS Lipman","year":"2015","journal-title":"High Alt Med Biol"},{"issue":"7443","key":"pone.0345796.ref062","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/bmj.38043.501690.7C","article-title":"Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)","volume":"328","author":"JH Gertsch","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"pone.0345796.ref063","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/ham.2006.7.17","article-title":"Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: The prophylactic acetazolamide dosage comparison for efficacy (PACE) trial","volume":"7","author":"B Basnyat","year":"2006","journal-title":"High Alt Med Biol"},{"issue":"3","key":"pone.0345796.ref064","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jnnp.2007.124727","article-title":"Gabapentin for prevention of hypobaric hypoxia-induced headache: Randomized double-blind clinical trial","volume":"79","author":"S Jafarian","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"pone.0345796.ref065","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1468-2982.2007.01387.x","article-title":"Low-dose gabapentin in treatment of high-altitude headache","volume":"27","author":"S Jafarian","year":"2007","journal-title":"Cephalalgia"},{"key":"pone.0345796.ref066","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1515\/folmed-2015-0036","article-title":"Heart rate variability as a method for assessment of the autonomic nervous system and the adaptations to different physiological and pathological conditions","volume":"57","author":"ZZ Taralov","year":"2015","journal-title":"Folia Med (Plovdiv)"},{"issue":"7","key":"pone.0345796.ref067","first-page":"742","article-title":"Acute mountain sickness and ascent rates in trekkers above 2500 m in the Nepali Himalaya","volume":"77","author":"J Vardy","year":"2006","journal-title":"Aviat Space Environ Med"},{"issue":"12","key":"pone.0345796.ref068","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/rccm.201207-1323CI","article-title":"High-altitude medicine","volume":"186","author":"JB West","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0345796.ref069","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mam.2015.12.002","article-title":"Oxygen-sensing by arterial chemoreceptors: Mechanisms and medical translation","author":"J L\u00f3pez-Barneo","year":"2016","journal-title":"Mol Aspects Med"},{"issue":"5","key":"pone.0345796.ref070","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.jcbfm.9600404","article-title":"Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness","volume":"27","author":"K Kallenberg","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"pone.0345796.ref071","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1152\/japplphysiol.00391.2011","article-title":"Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study","volume":"111","author":"CG Julian","year":"2011","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0345796.ref072","article-title":"Wilderness medical society clinical practice guidelines for the prevention, diagnosis, and treatment of acute altitude illness: 2024 update","volume":"35","author":"AM Luks","year":"2024","journal-title":"Wilderness Environ Med"},{"issue":"4","key":"pone.0345796.ref073","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/ham.2010.1030","article-title":"Evidence for a genetic basis for altitude illness: 2010 update","volume":"11","author":"MJ MacInnis","year":"2010","journal-title":"High Alt Med Biol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:28:11Z","timestamp":1775842091000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345796"}},"subtitle":[],"editor":[{"given":"UDAYAN","family":"BHATTACHARYA","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345796","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}